Refractory glaucoma often requires vision-sparing trabeculectomy. To increase surgical
success, adjunctive pharmacotherapy is utilized albeit the risk of adverse events. This
prospective trial randomizes adults with uncontrolled glaucoma to assess an emerging healing
modulatory strategy. Over a 1-year follow-up, trabeculectomy complemented with intracameral
delivery of anti-angiogenic bevacizumab (1.25 mg) is compared to standard trabeculectomy with
anti-fibrotic mitomycin-C (0.02%; applied for 2 minutes).